Immunome (IMNM) CFO uses options, sells 60,000 shares under 10b5-1 plan

Rhea-AI Filing Summary

Immunome Inc. Chief Financial Officer Max Rosett reported an exercise-and-sale transaction in company stock. He exercised stock options covering 60,000 shares of common stock at an exercise price of $1.05 per share and, on the same date, sold 60,000 shares of common stock in open-market transactions.

The weighted average sale price was $18.23 per share, with individual trade prices ranging from $17.95 to $18.66. These sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on December 26, 2025. Following the transactions, Rosett directly holds 54,037 shares of Immunome common stock, and the exercised option is now fully vested and fully exercised.

Insider Trade Summary 10b5-1

Net Seller: 60,000 shares ($1,093,800)

Net Sell 3 txns

Insider Rosett Max

Role Chief Financial Officer

Sold 60,000 shs ($1.09M)

Type	Security	Shares	Price	Value
Exercise	Stock Option (right to buy)	60,000	$0.00	--
Exercise	Common Stock	60,000	$1.05	$63K
Sale	Common Stock	60,000	$18.23	$1.09M

Holdings After Transaction: Stock Option (right to buy) — 0 shares (Direct, null); Common Stock — 114,037 shares (Direct, null)

Footnotes (1)

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 26, 2025. The weighted average purchase price for the transaction report was $18.23, and the range of prices were between $17.95 and $18.66, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided. The option is fully vested.

Key Figures

Shares sold: 60,000 shares Weighted average sale price: $18.23 per share Option exercise size: 60,000 shares +4 more

7 metrics

Shares sold 60,000 shares Common Stock sold in open-market transactions on 2026-06-15

Weighted average sale price $18.23 per share Common Stock sales, price range $17.95–$18.66

Option exercise size 60,000 shares Stock option exercised into common stock on 2026-06-15

Option exercise price $1.05 per share Exercise price for stock option (right to buy)

Shares held after transaction 54,037 shares Common Stock directly owned by CFO after transactions

10b5-1 plan adoption date December 26, 2025 Date CFO adopted Rule 10b5-1 trading plan governing sales

Option expiration March 22, 2033 Expiration date of stock option that was exercised

Key Terms

Rule 10b5-1 trading plan, Stock Option (right to buy), weighted average purchase price, derivative exercise/conversion, +1 more

5 terms

Rule 10b5-1 trading plan regulatory

"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 26, 2025."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

Stock Option (right to buy) financial

"security_title: "Stock Option (right to buy)""

weighted average purchase price financial

"The weighted average purchase price for the transaction report was $18.23, and the range of prices were between $17.95 and $18.66, inclusive."

The weighted average purchase price is the average cost per share you paid across multiple buys, calculated so larger purchases count more than smaller ones. Imagine buying apples at different prices: the overall price you effectively paid depends on how many apples you bought at each price. Investors use it to measure true cost basis, calculate gains or losses, decide when to sell, and manage taxes and portfolio performance.

derivative exercise/conversion financial

"transaction_action: "derivative exercise/conversion""

fully vested financial

"The option is fully vested."

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Rosett Max

(Last) (First) (Middle)

C/O IMMUNOME, INC.

18702 N. CREEK PARKWAY, SUITE 100

(Street)

BOTHELL WASHINGTON 98011

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Immunome Inc. [ IMNM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/15/2026		M		60,000	A	$1.05	114,037	D
Common Stock	06/15/2026		S(1)		60,000	D	$18.23(2)	54,037	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$1.05	06/15/2026		M			60,000	(3)	03/22/2033	Common Stock	60,000	$0	0	D

Explanation of Responses:

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 26, 2025.

2. The weighted average purchase price for the transaction report was $18.23, and the range of prices were between $17.95 and $18.66, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.

3. The option is fully vested.

	/s/ Sandra Stoneman, Attorney-in-Fact	06/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Immunome (IMNM) CFO Max Rosett report in this Form 4?

Immunome CFO Max Rosett reported exercising stock options for 60,000 common shares and selling 60,000 shares in open-market transactions. The activity represents an exercise-and-sale pattern rather than a new open-market purchase of stock.

At what prices did Immunome (IMNM) CFO Max Rosett sell shares?

Max Rosett’s reported sale had a weighted average price of $18.23 per share, with individual trades ranging between $17.95 and $18.66. These transactions occurred in the open market on the same date as the option exercise.

How many Immunome (IMNM) shares does the CFO hold after this transaction?

After the reported transactions, CFO Max Rosett directly holds 54,037 shares of Immunome common stock. This figure reflects his position after exercising 60,000 options and selling 60,000 common shares on the reported transaction date.

Were the Immunome (IMNM) CFO’s stock sales made under a 10b5-1 plan?

Yes. The filing states the sales were effected under a Rule 10b5-1 trading plan adopted by Max Rosett on December 26, 2025. Such plans are pre-arranged and can make the timing of trades more routine and less discretionary.

What were the terms of the exercised Immunome (IMNM) stock options?

The CFO exercised stock options for 60,000 shares of Immunome common stock at an exercise price of $1.05 per share. The option was fully vested and, after this transaction, the derivative position reported for this option shows no remaining shares.